DOCSLIB.ORG

Poisons List (Jersey) Order, 1986. ______

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Poisons List (Jersey) Order, 1986. ______ 1 Jersey R & O 7526 Pharmacy, Poisons and Medicines (Jersey) Law, 1952. ____________ POISONS LIST (JERSEY) ORDER, 1986. ____________ THE PUBLIC HEALTH COMMITTEE, in pursuance of Article 15 of the Pharmacy, Poisons and Medicines (Jersey) Law, 1952, as amended,1 hereby orders as follows – 1. The list of substances which are to be treated as poisons for the purposes of the Pharmacy, Poisons and Medicines (Jersey) Law, 1952,2 shall be as set out in the Schedule to this Order. 2. The Poisons List (Jersey) Order, 1969,3 the Poisons List (Amendment) (Jersey) Order, 1972,4 the Poisons List (Amendment No. 2) (Jersey) Order, 19745 and the Poisons List (Amendment No. 3) (Jersey) Order, 19756 are revoked. 3. This Order may be cited as the Poisons List (Jersey) Order, 1986 and shall come into force forthwith. By Order of the Public Health Committee, E.J.M. POTTER Greffier of the States. 23rd July, 1986. 1 Recueil des Lois, Tome VIII, page 125. 2 Recueil des Lois, Tome VIII, page 111. 3 No. 5220. 4 No. 5706. 5 No. 6046. 6 No. 6109. 2 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 SCHEDULE (Article 1) THE POISONS LIST PART I (Poisons which, subject to the provisions of the Pharmacy, Poisons and Medicines (Jersey) Law, 1952, are not to be sold except by a person who is an authorised seller of poisons.) Acebutolol Hydrochloride Acetanilide; alkyl acetanilides Acetarsol Acetazolamide Sodium Acetazolamide Acetohexamide Acetorphine; its salts; its esters and ethers; their salts Acetylcarbromal Acetylcholine Chloride Acetylcysteine Acetyldigitoxin Acetyldihydrocodeine; its salts Acetylstrophanthidin 3 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Aconite Root Aconite Acrosoxacin Actinomycin C Actinomycin D Acyclovir Adicillin Adiphenine Hydrochloride Adrenocortical Extract Aklomide Alclofenac Alcuronium Chloride Aldosterone Alfacalcidol Alkali flourides other than those specified in Part II of this List Alkaloids, the following; their quaternary compounds; any salt, simple or complex, of any substance falling within the following – Aconite, alkaloids of Atropine Belladonna, alkaloids of Brucine Calabar bean, alkaloids of Coca, alkaloids of 4 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Cocaine Codeine; its esters and ethers Colchicum, alkaloids of Coniine Cotarnine Curare, alkaloids of; curare bases Ecgonine; its esters and ethers Emetine Ephedra, alkaloids of Ergot, alkaloids of, whether hydrogenated or not; their homologues Gelsemium, alkaloids of Homatropine Hyoscine Hyoscyamine Jaborandi, alkaloids of Lobelia, alkaloids of Morphine, its esters and ethers Papaverine Pomegranate, alkaloids of Quebracho, alkaloids of, other than the alkaloids of red quebracho Rauwolfia; alkaloids of; their derivatives Sabadilla, alkaloids of Solanaceous alkaloids not otherwise included in this List Stavesacre, alkaloids of Strychnine Thebaine Veratrum, alkaloids of Yohimba, alkaloids of Allergen Extracts Allopurinol Allylisopropylacetylurea Allylprodine; its salts 5 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Alphadolone Acetate Alphameprodine; its salts Alphaprodine; its salts Alphaxalone Alprazolam Alprenolol Alprenolol Hydrochloride Alprostadil Alseroxylon Altizide Aluminium phosphide Amantadine Hydrochloride Ambenonium Chloride Ambuside Ambutonium Bromide Amcinonide Ametazole Hydrochloride Amidopyrine; its salts; amidopyrine sulphonates; their salts Amikacin Sulphate Amiloride Hydrochloride 6 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Amino-alcohols esterified with benzoic acid, phenylaceticacid, phenylpropionic acid, cinnamic acid or the derivatives of these acids; their salts p-Aminobenzenesulphonamide; its salts; derivatives of p- aminobenzenesulphonamide having any of the hydrogen atoms of the p- amino group or of the sulphonamide group substituted by anotherradical; their salts p-Aminobenzoic acid, esters of; their salts Aminocaproic Acid Aminoglutethimide Aminopterin Sodium Aminorex; its salts Aminosalicylic Acid Amiodarone Hydrochloride Amiphenazole Hydrochloride Amitriptyline; its salts Ammonium Bromide Amoxapine Amoxycillin Amoxycillin Trihydrate Amphomycin Amphomycin Calcium 7 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Amphotericin Ampicillin Ampicillin Sodium Ampicillin Trihydrate Amygdalin Amyl nitrite Amylocaine Hydrochloride Ancrod Androgenic, oestrogenic and progestational substances the following – Benzoestrol Derivatives of stilbene, dibenzyl or naphthalene with oestrogenic activity; their esters Steroid compounds with androgenic or oestrogenic or progestational activity; their esters Angiotensin Amide Anileridine; its salts Anterior Pituitary Extract Anti-histamine substances, the following; their salts; their molecular compounds – Antazoline Bromodiphenhydramine Buclizine Carbinoxamine 8 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Chlorcyclizine Chlorpheniramine Cinnarizine Clemizole Cyclizine Cyproheptadine 3-Di-n-butylaminomethyl-4,5,6-trihydroxyphthalide Diphenhydramine Diphenylpyraline Doxylamine Isothipendyl Mebhydrolin Meclozine Phenindamine Pheniramine Phenyltoloxamine Promethazine Pyrrobutamine Thenalidine Tolpropamine Triprolidine Substances being tetra-N-substituted derivatives of ethylenediamine or propylenediamine Antimony, chlorides of; oxides of antimony; sulphides of antimony; antimonates; antimonites; organic compounds of antimony Apiol Apomorphine; its salts Apramycin Apramycin Sulphate Aprotinin Arecoline 9 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Arecoline-Acetarsol Arecoline Hydrobromide Arprinocid Arsanilic Acid Arsenic Arsenical substances, the following, except those specified in Part II of this List; halides of arsenic; oxides of arsenic; arsenates; arsenites; organic compounds of arsenic Atenolol Azacyclonal; its salts Azaperone Azapropazone Azathioprine Azathioprine Sodium Azidocillin Potassium Azlocillin Sodium Bacampicillin Hydrochloride Bacitracin Bacitracin Methylene Disalicylate Bacitracin Zinc Baclofen 10 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Bambermycin Barbituric acid; its salts; derivatives of barbituric acid; their salts; compounds of barbituric acid; its salts; its derivatives, their salts, with any other substance Barium Carbonate Barium, salts of, other than barium sulphate and the salts of barium specified in Part II of this List Beclamide Beclomethasone Beclomethasone Diproprionate Belladonna Herb Belladonna Root Bemegride Bemegride Sodium Benactyzine; its salts Benapryzine Benethamine Penicillin Benoxaprofen Benperidol Benserazide Benzathine Penicillin 11 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Benzbromarone Benzethidine; its salts Benzhexol; its salts Benzilonium Bromide Benzoctamine; its salts Benzoylmorphine; its salts Benzoyl Peroxide Benzquinamide Benzquinamide Hydrochloride Benztropine and its homologues; their salts Benzylmorphine; its salts Benzylpenicillin Benzylpenicillin Calcium Benzylpenicillin Potassium Benzylpenicillin Sodium Betahistine dihydrochloride Betameprodine; its salts Betamethasone Betamethasone Adamantoate Betamethasone Benzoate 12 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Betamethasone Sodium Phosphate Betamethasone Valerate Betaprodine; its salts Bethanechol Chloride Bethanidine Sulphate Biperiden Hydrochloride Biperiden Lactate Bleomycin Bleomycin Sulphate Boldenone Undecylenate Bretylium Tosylate Bromhexine Hydrochloride Bromocriptine Mesylate Bromomethane Bromvaletone Brotizolam Budesonide Bufexamac Bumetanide Buphenine Hydrochloride 13 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Bupivacaine Bupivacaine Hydrochloride Buprenorphine Buprenorphine Hydrochloride Busulphan; its salts Butanilicaine Phosphate Butriptyline Hydrochloride Butylchloral Hydrate Calcitonin Calcitriol Calcium Aminosalicylate Calcium Amphomycin Calcium Benzamidosalicylate Calcium Bromide Calcium Bromidolactobionate Calcium Carbimide Calcium Folinate Calcium Metrizoate Candicidin 14 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Cannabinol and its tetrahydro derivatives, prepared wholly or partly by synthesis; their 3-alkyl homologues; any esters or ether of any substance falling within this item Cannabis (the dried flowering or fruiting tops of Cannabis Sativa Linn); the resin of cannabis; extracts of cannabis; tinctures of cannabis; cannabin tannate Canrenoic Acid Cantharidin; cantharidates Capreomycin Sulphate Captodiame; its salts Caramiphen; its salts Carbachol Carbadox Carbamazepine Carbenicillin Sodium Carbenoxolone Sodium Carbidopa Carbidopa Monohydrate Carbimazole Carbocisteine Carbon Tetrachloride Carboprost Trometamol 15 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Carbromal Carbuterol Hydrochloride Carfecillin Sodium Carindacillin Sodium Carisoprodol Carmustine Carperidine; its salts Cefaclor Cefadroxil Cefazedone Sodium Cefotaxime Sodium Cefoxitin Sodium Cefsulodin Sodium Cefuroxime Sodium Cephalexin Cephalexin Sodium Cephaloglycin Cephaloram Cephaloridine Cephalosporin C 16 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Cephalosporin E Cephalosporin N Cephalothin Sodium Cephamandole Nafate Cephazolin Sodium Cephradine Cerium Oxalate Chenodeoxycholic Acid Chloral; its addition and its condensation products other than alpha- chloralose; their molecular compounds Chloralose Chloralurethane Chlorambucil Chloramphenicol Chloramphenicol Cinnamate Chloramphenicol Palmitate Chloramphenicol Sodium Succinate Chlordiazepoxide; its salts Chlorhexadol Chlorisondamine Chloride 17 Jersey R & O 7526 Poisons List (Jersey) Order, 1986 Chlormadinone Acetate Chlormerodrin Chlormethiazole;
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • 1532 Corticosteroids
    1532 Corticosteroids olone; Ultraderm; Malaysia: Synalar†; Mex.: Cortifung-S; Cortilona; Gr.: Lidex; Ital.: Flu-21†; Topsyn; Mex.: Topsyn; Norw.: Metosyn; Pharmacopoeias. In Br. Cremisona; Farmacorti; Flumicin; Fluomex; Fusalar; Lonason; Synalar; Philipp.: Lidemol; Lidex; Singapore: Lidex†; Spain: Klariderm†; Novoter; BP 2008 (Fluocortolone Hexanoate). A white or creamy-white, Norw.: Synalar; NZ: Synalar; Philipp.: Aplosyn; Cynozet; Synalar; Syntop- Switz.: To p s y m ; To p s y m i n ; UK: Metosyn; USA: Lidex; Vanos. ic; Pol.: Flucinar; Port.: Oto-Synalar N; Synalar; Rus.: Flucinar (Флуцинар); odourless or almost odourless, crystalline powder. It exhibits pol- Multi-ingredient: Austria: Topsym polyvalent; Ger.: Jelliproct; Topsym ymorphism. Practically insoluble in water and in ether; very Sinaflan (Синафлан); S.Afr.: Cortoderm; Fluoderm; Synalar; Singapore: polyvalent; Hung.: Vipsogal†; Israel: Comagis; Mex.: Topsyn-Y; Philipp.: Flunolone-V; Spain: Co Fluocin Fuerte; Cortiespec; Fluocid Forte; Fluoder- Lidex NGN; Spain: Novoter Gentamicina; Switz.: Mycolog N; Topsym slightly soluble in alcohol and in methyl alcohol; slightly soluble mo Fuerte; Flusolgen; Gelidina; Intradermo Corticosteroi†; Synalar; Synalar polyvalent; UK: Vipsogal. in acetone and in dioxan; sparingly soluble in chloroform. Pro- Rectal Simple; Swed.: Synalar; Switz.: Synalar; Thai.: Cervicum; Flu- ciderm†; Flunolone-V; Fulone; Supralan; Synalar; UK: Synalar; USA: Capex; tect from light. Derma-Smoothe/FS; DermOtic; Fluonid; Flurosyn†; Retisert; Synalar; Syn- emol; Venez.: Bratofil; Fluquinol Simple†; Neo-Synalar; Neoflu†. Fluocortin Butyl (BAN, USAN, rINNM) ⊗ Fluocortolone Pivalate (BANM, rINNM) ⊗ Multi-ingredient: Arg.: Adop-Tar†; Tri-Luma; Austria: Myco-Synalar; Procto-Synalar; Synalar N; Belg.: Procto-Synalar; Synalar Bi-Otic; Braz.: Butil éster de la fluocortina; Butylis Fluocortinas; Fluocortine Fluocortolone, pivalate de; Fluocortolone Trimethylacetate; Dermobel†; Dermoxin; Elotin; Fluo-Vaso; Neocinolon; Otauril†; Otocort†; Butyle; SH-K-203.
    [Show full text]
  • Poisons Act.Fm
    LAWS OF BRUNEI CHAPTER 114 POISONS Enactment No. 13 of 1956 Amended by S 103/1958 Enactment No. 6 of 1967 S 101/1979 1984 Edition, Chapter 114 Amended by S 16/1996 S 28/2001 GN 273/2002 REVISED EDITION 2015 B.L.R.O. 1/2015 LAWS OF BRUNEI Poisons CAP. 114 1 LAWS OF BRUNEI REVISED EDITION 2015 CHAPTER 114 POISONS ARRANGEMENT OF SECTIONS Section 1. Citation. 2. Interpretation. 3. Description of poisons. 4. Licensing Officers. 5. General prohibition with respect to importation and sale of poisons. 6. Prohibitions and provisions relating to sale of poisons. 7. Exemptions in respect of medicines. 8. Exemptions in respect of sale. 9. Possession of poisons. 10. Issue of licences. 11. Different kinds of licence. 12. Licences to be numbered and registered. 13. Annual list to be published. 14. Forms of licence. 15. Search and search warrants. 16. Powers of exemption. 17. Penalties. B.L.R.O. 1/2015 LAWS OF BRUNEI 2 CAP. 114 Poisons 18. Jurisdiction. 19. Prosecutions. 20. Prohibition of sale to persons under 18. 21. Rules. SCHEDULE — POISONS LIST ____________________________ LAWS OF BRUNEI Poisons CAP. 114 3 POISONS ACT An Act to regulate the importation, possession, manufacture, compounding, storage, transport and sale of poisons Commencement: 1st January 1983 [S 61/1957] Citation. 1. This Act may be cited as the Poisons Act. Interpretation. 2. In this Act, unless the context otherwise requires — “dentist” means a dentist licensed under the Medical Practitioners and Dentists Act (Chapter 112) and includes a Government dentist; “export”, in relation
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • University of Groningen Multi-Residue Analysis of Growth Promotors In
    University of Groningen Multi-residue analysis of growth promotors in food-producing animals Koole, Anneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1998 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Koole, A. (1998). Multi-residue analysis of growth promotors in food-producing animals. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 APPENDIX 1 OVERVIEW OF RELEVANT SUBSTANCES This appendix consists of two parts. First, substances that are relevant for the research presented in this thesis are given. For each substance CAS number (CAS), molecular weight (MW), bruto formula (formula) and if available UV maxima and alternative names are given. In addition, pKa values for the ß-agonists are listed, if they were available.
    [Show full text]